Singapore markets closed
  • Straits Times Index

    3,205.14
    +16.64 (+0.52%)
     
  • Nikkei

    28,804.85
    +96.27 (+0.34%)
     
  • Hang Seng

    26,126.93
    +109.40 (+0.42%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • BTC-USD

    60,867.68
    -1,926.46 (-3.07%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • FTSE Bursa Malaysia

    1,588.08
    -3.54 (-0.22%)
     
  • Jakarta Composite Index

    6,643.74
    +10.77 (+0.16%)
     
  • PSE Index

    7,289.61
    -22.11 (-0.30%)
     

Could This News Spark a Turnaround for Ocugen?

·4-min read
Could This News Spark a Turnaround for Ocugen?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Ocugen (NASDAQ: OCGN) shares were flying high earlier this year. The company signed a deal with India's Bharat Biotech for co-commercialization rights to its coronavirus vaccine candidate in the U.S. The Bharat product was close to market. Since then, Ocugen learned it wouldn't win the right to sell the vaccine in the U.S. as soon as it had hoped.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting